
    
      This is a Phase 3, multicentre, multinational, randomised, double-blind, placebo-controlled
      study to evaluate the efficacy and safety of an intravenous treatment regimen of two doses of
      anifrolumab versus placebo in subjects with moderately to severely active,
      autoantibody-positive systemic lupus erythematosus (SLE) while receiving standard of care
      (SOC) treatment. The study will be performed in adult subjects aged 18 to 70 years of age.
    
  